HRT Financial’s Standard BioTools LAB Stock Holding History

HRT Financial’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-70,522	Closed	-$64K	–	4828
2026 Q1	$64K	Sell	70,522 -23,260	-25%	-$28.2K	﹤0.01%	3419
2025 Q4	$120K	Buy	+93,782	New	+$126K	﹤0.01%	2758
2024 Q2	–	Sell	-507,417	Closed	-$1.38M	–	2683
2024 Q1	$1.38M	Buy	+507,417	New	+$1.22M	0.01%	735
2023 Q3	–	Sell	-11,877	Closed	-$22K	–	2779
2023 Q2	$22K	Buy	+11,877	New	+$23.4K	﹤0.01%	2090
2022 Q1	–	Sell	-42,758	Closed	-$167K	–	3492
2021 Q4	$167K	Sell	42,758 -90	-0.2%	-$421	﹤0.01%	2600
2021 Q3	$282K	Buy	+42,848	New	+$282K	﹤0.01%	2446
2021 Q2	–	Sell	-10,628	Closed	-$48K	–	3200
2021 Q1	$48K	Sell	10,628 -103,668	-91%	-$569K	﹤0.01%	2548
2020 Q4	$685K	Buy	+114,296	New	+$751K	0.01%	855
2019 Q4	–	Sell	-18,209	Closed	-$84K	–	1415
2019 Q3	$84K	Buy	+18,209	New	+$143K	﹤0.01%	1257

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

HRT Financial's LAB Position: Q2 2026 in Review

HRT Financial sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 70,522 shares — an estimated $64K sold.

HRT Financial first reported a position in LAB in Q3 2019 and held it in 9 quarters. The position peaked at $1.38M in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

HRT Financial reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 70,522 Standard BioTools shares in Q2 2026, an estimated $64K.
HRT Financial first reported a position in Standard BioTools in Q3 2019 and held it in 9 quarters.
HRT Financial's Standard BioTools position peaked at $1.38M in Q1 2024.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.